Report of a clinical trial of a Canadian preparation of antihemophilic factor.
A clinical trial of a Canadian preparation of antihemophilic factor has been completed. The mean percentage increase in the factor VIII coagulant activity in the plasma was determined to be 2.1 +/- 0.8 per unit per kilogram dose, which compares very favourably with published data. The mean half-life of antihemophilic factor was found to be 14.7 hours. Side effects and reactions to the product were minimal and the product has been rated as clinically effective. No significant differences between lots were noted in the in vivo response or the half-life.
D000293:Adolescent; D000328:Adult; D001780:Blood Coagulation Tests; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005169:Factor VIII / Q000627:therapeutic use*; D005260:Female; D006207:Half-Life; D006467:Hemophilia A / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D008297:Male; D011247:Pregnancy
D005169:Factor VIII